Ion Beam Applications SA (IBAB.BR)
28 Jul 2014
|Market Cap (Mil.):||€332.72|
|Shares Outstanding (Mil.):||28.20|
BRUSSELS, July 16 - Belgian radiotherapy company IBA said on Wednesday it had gained U.S. approval for a key technology, which it said should spur more interest in its newer, compact cancer treatment centres.
* IBA signs contract to install a 70 mev cyclotron for to production of radiopharmaceuticals in Russia
* Iba sa : iba selected to install first proton therapy center at umcg in netherlands
BRUSSELS, May 14 - Belgian cancer diagnosis and therapy company Ion Beam Applications maintained its revenue outlook for 2014 on Wednesday even though sales in the first three months came in below target.
BRUSSELS, May 14 - Belgian cancer diagnosis and therapy company Ion Beam Applications maintained its revenue outlook for 2014 even though sales in the first three months came in below target.
* Revenues of 46.3 mln euros, up 4 pct compared to same period in 2013
BRUSSELS, March 26 - Proton therapy group IBA on Wednesday said it expected revenues to grow by between 5 and 10 percent in 2014, driven by demand for its new products.
BRUSSELS, March 26 - Ion Beam Applications SA : * Combination of Dosimetry and Service revenues grew to 42 pct of total group revenues in 2013 * For 2014 confirmed: 5-10 pct top line growth with 10 pct operating profit * Top line impacted by FX and slowdown in US radiotherapy market for dosimetry, low conversion rate of PT projects * Reported net profit before technical recycling of currency translation adjustment to income statement reached 6.1 mln euros * We entered 2014 with a
BRUSSELS, March 26 - Ion Beam Applications SA : * Says IBA signs final contract with westdeutsches protonentherapiezentrum Essen * Finalizes the acquisition of the proton therapy center in Essen from Striba Protonentherapiezentrum GMBH * No additional p&l effects beyond what was stated in co's 2013 first half
BRUSSELS, March 17 - Ion Beam Applications SA : * Says IBA closes agreement to divest PharmaLogic pet services of Montreal company assets * About 85 percent of price has been paid to PharmaLogic at closing and rest will be released after a two year period * Says payments will then be distributed as dividends to PharmaLogic's shareholders, including IBA * Says expects a net total cash inflow in dividend from this sale of about EUR 7.7 million * Deal will have no impact on 2013 acc
Earnings vs. Estimates
Analyst Research Reports
Ion Beam Applications SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.